Clinical trialNAUnknown
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
- Outcome
- Outcome unknown
- Phase
- NA
- Status
- Unknown
- Study type
- Interventional
- Start
- 9 December 2021
- Expected end
- December 2024
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- MPR
- Sponsor
- Other
- Results posted
- No
- Last update
- 29 March 2023
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09 PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Papers 2
- Builds on itEfficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemother… DOI 10.1007/s00259-025-07115-3↗
- Builds on itPreclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for … DOI 10.1007/s00259-023-06373-3↗